NASDAQ:REGN

Regeneron Pharmaceuticals Stock Forecast, Price & News

$528.75

+3.20 (+0.61 %)

(As of 06/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$521.96

▼

$529.29

50-Day Range

$472.80

▼

$532.04

52-Week Range

$441.00

▼

$664.64

Volume497,799 shs

Average Volume925,757 shs

Market Capitalization$56.34 billion

P/E Ratio14.97

Dividend YieldN/A

Beta0.2

30 days | 90 days | 365 days | Advanced Chart

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

2 Reasons Why This FDA Decision Could Add Billions to Regeneron's Revenue
June 12, 2021 | finance.yahoo.com

REGN vs. INCY: Which Stock Should Value Investors Buy Now?
June 11, 2021 | finance.yahoo.com

Following Up on Our Regeneron Recommendation
June 9, 2021 | finance.yahoo.com

Merck Cuts a Billion-Dollar COVID Deal
June 9, 2021 | finance.yahoo.com

3 Growth Stocks at a Reasonable Prices
June 8, 2021 | stocknews.com

Company News for Jun 7, 2021
June 7, 2021 | finance.yahoo.com

FDA Authorizes Lower Regeneron Covid-19 Antibody Dose. What That Means for the Stock.
June 4, 2021 | finance.yahoo.com

FDA Updates EUA For REGEN-COV With Lower Dosage Of 1,200 Mg
June 4, 2021 | finanznachrichten.de

FDA Updates EUA For REGEN-COV With Lower Dosage Of 1,200 Mg - Quick Facts
June 4, 2021 | markets.businessinsider.com

Regeneron’s Covid-19 Drug Is Authorized for Injection
June 4, 2021 | wsj.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
Previous Symbol
CUSIP75886F10
CIK872589
Webwww.regeneron.com
Phone914-847-7000
Employees9,123
Year Founded1988

Sales & Book Value

Annual Sales$8.50 billion
Price / Sales6.63
Cash Flow$33.61 per share
Price / Cash Flow15.73
Book Value$102.91 per share
Price / Book5.14

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares106,544,000
Market Cap$56.34 billion
Next Earnings Date8/4/2021 (Estimated)
OptionableOptionable

Social Links

MarketRank^™

Overall MarketRank^™

1.83 out of 5 stars

Medical Sector

174th out of 2,100 stocks

Pharmaceutical Preparations Industry

79th out of 832 stocks

2.4 Analyst's Opinion

Consensus Rating
Regeneron Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 12 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $656.11, Regeneron Pharmaceuticals has a forecasted upside of 24.1% from its current price of $528.75.
Amount of Analyst Coverage
Regeneron Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Regeneron Pharmaceuticals has received 1,384 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Regeneron Pharmaceuticals has received 1,292 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Regeneron Pharmaceuticals has received 51.72% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote “Outperform” if you believe REGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Regeneron Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Regeneron Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $495,630.00 in company stock.
Percentage Held by Insiders
Only 11.84% of the stock of Regeneron Pharmaceuticals is held by insiders.
Percentage Held by Institutions
83.03% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5 Earnings and Valuation

Earnings Growth
Earnings for Regeneron Pharmaceuticals are expected to decrease by -17.80% in the coming year, from $46.81 to $38.48 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Regeneron Pharmaceuticals is 14.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.86.
Price to Earnings Ratio vs. Sector
The P/E ratio of Regeneron Pharmaceuticals is 14.97, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.87.
Price to Earnings Growth Ratio
Regeneron Pharmaceuticals has a PEG Ratio of 0.61. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Regeneron Pharmaceuticals has a P/B Ratio of 5.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

Is Regeneron Pharmaceuticals a buy right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Regeneron Pharmaceuticals?

Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Regeneron Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Regeneron Pharmaceuticals.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its earnings results on Thursday, May, 6th. The biopharmaceutical company reported $9.89 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $7.78 by $2.11. The biopharmaceutical company earned $2.53 billion during the quarter, compared to the consensus estimate of $2.69 billion. Regeneron Pharmaceuticals had a net margin of 43.53% and a trailing twelve-month return on equity of 35.43%. The firm's quarterly revenue was up 38.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.60 earnings per share.
View Regeneron Pharmaceuticals' earnings history.

How has Regeneron Pharmaceuticals' stock been impacted by Coronavirus?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, REGN shares have increased by 13.8% and is now trading at $528.75.
View which stocks have been most impacted by COVID-19.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals declared that its Board of Directors has approved a share buyback program on Tuesday, November 5th 2019, which authorizes the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 2.9% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

What price target have analysts set for REGN?

16 Wall Street analysts have issued 1 year price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $495.00 to $800.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $656.11 in the next twelve months. This suggests a possible upside of 24.1% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:

Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 68, Pay $5.35M)
Dr. George D. Yancopoulos, Co-Founder, Pres & Chief Scientific Officer & Director (Age 61, Pay $4.38M) (LinkedIn Profile)
Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 57, Pay $1.79M) (LinkedIn Profile)
Dr. Andrew J. Murphy, Exec. VP of Research (Age 63, Pay $1.64M)
Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 48, Pay $1.79M)
Ms. Patrice Gilooly, Sr. VP of Quality Assurance & Operations
Mr. Christopher R. Fenimore, Sr. VP, Head of Accounting & Controller (Age 50)
Mr. Gerald Underwood, Sr. VP of Technical Operations
Mr. Bob McCowan, Sr. VP of IT & Chief Information Officer
Justin Holko, VP of Investor Relations

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees.

Who are some of Regeneron Pharmaceuticals' key competitors?

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of REGN's competitors.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), The Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.01%), JPMorgan Chase & Co. (2.83%), Loomis Sayles & Co. L P (2.70%), Alliancebernstein L.P. (1.94%), Geode Capital Management LLC (1.50%) and Capital International Investors (1.20%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals.

Which major investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nuveen Asset Management LLC, Janus Henderson Group PLC, BlackRock Inc., Loomis Sayles & Co. L P, Capital International Investors, Brandywine Global Investment Management LLC, and Northern Trust Corp. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Joseph J Larosa, Joseph L Goldstein, Marion Mccourt, Michael S Brown, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Regeneron Pharmaceuticals stock?

REGN stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, JPMorgan Chase & Co., Acadian Asset Management LLC, Alliancebernstein L.P., Putnam Investments LLC, Neuberger Berman Group LLC, Woodline Partners LP, and FIL Ltd.
View insider buying and selling activity for Regeneron Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $528.75.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals has a market capitalization of $56.34 billion and generates $8.50 billion in revenue each year. The biopharmaceutical company earns $3.51 billion in net income (profit) each year or $28.66 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals employs 9,123 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Regeneron Pharmaceuticals: Loop Road Holdings LLC, OSMR Holdings, OSMR International, OSMR LLC, Old Saw Mill Holdings LLC, Regeneron Assurance, Regeneron Atlantic Holdings, Regeneron Belgium BVBA, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron Healthcare Solutions, Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron Spain, Regeneron UK Limited, and Rockwood Road Holdings LLC.

When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Where are Regeneron Pharmaceuticals' headquarters?

Regeneron Pharmaceuticals is headquartered at 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]

This page was last updated on 6/15/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here